Roivant Sciences Ltd.(ROIV)NASDAQ
Stock Overview & Analysis
Roivant Sciences Ltd. (ROIV) quick overview 2026-02-20
- The stock is currently trading at $27.15, experiencing a price strength within a larger uptrend—trading above its 50-day average while holding above the 200-day.
- Analysts appear optimistic, with a 1-year price target of $31.73 (16.9% upside).
- Volatility is elevated (70.41% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (-77.80% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Roivant Sciences Ltd. - Historical Price & Volume
Market Cap
Enterprise Value: $15.95B
P/E Ratio
Forward P/E: -21.83
Revenue Growth
Year over Year
Analyst Target
+16.9% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 68.60)
- Fundamentals say: Challenging (declining revenue trends)
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $108.94M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
Trading Range
Over the past year, the stock traded between $8.73 and $27.94—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 70.41% annualized volatility and β=1.23, the stock exhibits high sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
Roivant Sciences PHocus Trial Milestone Highlights Pipeline Progress And Valuation Gap
Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is evaluating mosliciguat as a potential first in class therapy for PH ILD, a serious condition with limited treatment options. Completion of enrollment marks a key operational step as the program advances toward Phase 2 data readouts. For Roivant Sciences (NasdaqGS:ROIV), this milestone comes...
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating. The firm cited encouraging Phase 2 data for brepocitinib in cutaneous sarcoidosis, an inflammatory condition affecting the skin. The drug’s […]
Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential
This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out
American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising the price target on the stock to $38 from $28 and maintaining a Buy rating. The rating update came the same day Roivant Sciences […]
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum
Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, month and past 3 months. See our latest analysis for Roivant Sciences. That sharp 22.1% 1 day share price return sits on top of a solid trend, with the 90 day share price return of 22.0% contributing to a 1 year total shareholder return of 137.1%, which suggests momentum has been building rather...
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts
Roivant Sciences has seen its price target narrative tighten up rather than swing wildly, with the model fair value estimate held at US$27.0 per share while the discount rate edges to 7.54% to reflect slightly higher required returns. This tweak largely comes from how analysts are weighing the timing of key batoclimab Phase 3 readouts, the litigation over Moderna royalties, and a catalyst path that now leans more heavily on 2026 events. Stay tuned as we break down what is driving these shifts...
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress
We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last week. Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares following encouraging results from its pipeline projects, with one already seeking a new drug application (NDA) […]
Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful
Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Roivant Sciences Ltd (ROIV) showcases promising pipeline progress and a strong cash position amidst ongoing challenges and opportunities.
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $27.15. The RSI (14-day) is at 68.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $31.73 implies 16.9% upside from current levels. Volatility is high at 70.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is -21.83. Price-to-Book is 4.54. Price-to-Sales is 1469.04. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ROIV, the consensus price target is $31.73. This represents a 16.9% upside from the current price of $27.15. The range spans from a low target of $22.00 to a high target of $38.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. High volatility (70.4% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-77.8% YoY), indicating potential business headwinds. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $108.94M. The debt-to-equity ratio is 2.19, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 30.66, indicating strong short-term liquidity. The quick ratio is 29.81. The company holds $4.53B in cash and equivalents. Free cash flow is negative at $-334,342,944, which could limit the company's ability to manage debt obligations.